Tirasemtiv
Unknown / undisclosed
Evidence outlook · program status
Discontinued (2017-11), after a negative readout
Tirasemtiv (CK-2017357) was Cytokinetics' first-generation fast skeletal muscle troponin activator in ALS. Its FY2017 Form 10-K states the Phase 3 VITALITY-ALS trial missed primary and secondary endpoints and that development was suspended; the same filing names reldesemtiv as the next-generation successor. The filing's word is 'suspend', and no tirasemtiv study has been registered in the nine years since. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
BENEFIT-ALS NCT01709149 · Amyotrophic Lateral Sclerosis The study used randomization and quadruple blinding with placebo control; 596 participants entered the double-blind phase, with 295 assigned to placebo and 301 to tirasemtiv. The primary functional outcome was not met: the least-squares difference was -0.58 ALSFRS-R points for tirasemtiv versus placebo (p=0.114), so the trial provides well-controlled but inconclusive evidence despite the large sample. Registry: NCT01709149 | 2 | The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment (Baseline, 8 weeks, 12 weeks) 2014-03 | The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind Treatment (Baseline, 8 weeks, 12 weeks): Tirasemtiv -2.98 units on a scale (Standard Error 0.277) vs Placebo -2.4 units on a scale (Standard Error 0.246) | Partial signal | link ↗ |
View 2 more trials
VITALITY-ALS NCT02496767 · Amyotrophic Lateral Sclerosis The study used randomized, triple-blind, placebo-controlled treatment in a large population, with 188 participants assigned to placebo and 126, 126, and 125 to the 250-, 375-, and 500-mg tirasemtiv groups. Its clinical respiratory primary endpoint was not met: none of the three tirasemtiv doses significantly improved slow vital capacity versus placebo. Registry: NCT02496767 | 3 | Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) (24 weeks) 2017-03-09 | Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC) (24 weeks): Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv -12.648 % predicted (Standard Error 1.5165) | Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv -13.742 % predicted (Standard Error 1.6076) | Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv -13.927 % predicted (Standard Error 1.7213) vs Double-blind, Placebo-controlled: Group 1 - Placebo -14.354 % predicted (Standard Error 1.227) | Partial signal | link ↗ |
NCT01378676 NCT01378676 · Amyotrophic Lateral Sclerosis The study was randomized, quadruple-blind, and placebo-controlled, with 49 participants assigned across multiple dose groups and a placebo group. Its primary safety and tolerability comparison cannot be judged because the registry provides no results, so the evidence is limited despite the controlled design. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with Adverse Events as a Measure of Safety and Tolerability". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT01378676 | 2 | Number of Participants with Adverse Events as a Measure of Safety and Tolerability (21 days) 2012-03 | Results not posted; external-source review pending | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.